3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
17
Head & Neck
9
Gastrointestinal
4
Thoracic
3
Breast
3
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
10
Thyroid Neoplasms
7
Lung Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Neuroendocrine
3
Small Cell Lung Carcinoma
2
Neuroendocrine Tumors
2
Carcinoma, Ovarian Epithelial
2
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Melanoma
1
Lethal Congenital Contracture Syndrome 2
1
Hypopharyngeal Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Medullary
1
Carcinoma, Large Cell
1
Breast Neoplasms
1
Interventions
3-Iodobenzylguanidine
3
olaparib
1
lutetium Lu 177 dotatate
1
entrectinib
1
entinostat
1
Pemetrexed
1
Paclitaxel
1
Dexamethasone
1
Calcium Dobesilate
1
Cabergoline
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Paclitaxel
×
Endocrine
×
Clear all
NCT00786552
2011-01-20
Panthera
University Hospital Schleswig-Holstein
Phase 2
Unknown
47 enrolled